Emmanuel Hanon, Vicebio CEO
September 23, 2024 03:00 AM EDT
Financing
Startups

UK vac­cine start­up Vice­bio snags $100M to take on GSK, Pfiz­er and Mod­er­na

Kyle LaHucik

Senior Reporter

The for­mer head of vac­cine R&D at GSK has pulled to­geth­er $100 mil­lion for a Lon­don-based biotech work­ing on res­pi­ra­to­ry vac­cines. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?

No­vo says its CB1 drug helped shed weight, but ef­fi­ca­cy and safe­ty ques­tions re­main

Biotech VC firm out­lines plans for $100M fund

FDA OKs the first-ever self-ad­min­is­tered vac­cine, for flu

FTC to sue ma­jor PBMs over in­sulin re­bates, claim­ing they in­flat­ed pa­tient cost

sponsored

PD­Cs vs. AD­Cs: A New Fron­tier in Tar­get­ed Can­cer Ther­a­pies and the Po­ten­tial for De­vel­op­ment Part­ner­ships

A service from the Financial Times